Multidrug therapy in a patient with Rabson-Mendenhall syndrome

Diabetologia

Volumn 53, Issue 11, 2010, Pages 2454-2455

  Moreira, Rodrigo O ^a,b,c   Zagury, R L ^a   Nascimento, T S ^c   Zagury, L ^a,b  

^a Instituto Estadual de Diabetes e Endocrinologia Luiz Capriglione   (Brazil)

^b PONTIFICAL CATHOLIC UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c UNIVERSIDADE PRESIDENTE ANTÔNIO CARLOS   (Brazil)

Author keywords

Pioglitazone; Rabson Mendenhall Syndrome; Severe Insulin Resistance; Vildagliptin

Indexed keywords

ACARBOSE; HEMOGLOBIN A1C; INSULIN; INSULIN RECEPTOR; METFORMIN; PIOGLITAZONE; VILDAGLIPTIN;

ACANTHOSIS NIGRICANS; ADOLESCENT; CASE REPORT; DRUG DOSE TITRATION; ENDOCRINE BONE DISEASE; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERANDROGENISM; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LETTER; MALE; MUTATIONAL ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NUTRITIONAL COUNSELING; PHYSICAL ACTIVITY; POLYPHARMACY; PRIORITY JOURNAL; PSEUDOACROMEGALY; RABSON MENDENHALL SYNDROME; SHORT STATURE; TOOTH MALFORMATION;

ADAMANTANE; ADOLESCENT; DIABETES MELLITUS, TYPE 2; DONOHUE SYNDROME; HUMANS; HYPOGLYCEMIC AGENTS; MALE; NITRILES; PYRROLIDINES; THIAZOLIDINEDIONES;

EID: 77957656069     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-010-1879-5     Document Type: Letter

References (6)

1. A Garg 2004 Acquired and inherited lipodystrophies New Engl J Med 350 1220 1234 1:CAS:528:DC%2BD2cXit12rtrk%3D 10.1056/NEJMra025261 15028826 (Pubitemid 38339366)
2. SI Taylor E Arioglu 1999 Genetically defined forms of diabetes in children J Clin Endocrinol Metab 84 4390 4396 1:CAS:528:DyaK1MXotVGrurs%3D 10.1210/jc.84.12.4390 10599693
3. C Musso E Cochran SA Moran, et al. 2004 Clinical course of genetic diseases of the insulin receptor (Type A and Rabson-Mendenhall syndromes) Medicine 83 209 222 1:CAS:528:DC%2BD2cXltlOkurY%3D 10.1097/01.md.0000133625. 73570.54 15232309 (Pubitemid 38955444)
4. Y Hattori H Satoh T Namatame, et al. 2006 A patient with extreme insulin resistance syndrome treated with pioglitazone Diab Care 29 2328 2329 10.2337/dc05-1249 (Pubitemid 44899879)
5. A Cama M de la Luz Sierra MJ Quon L Ottini P Gorden SI Taylor 1993 Substitution of glutamic acid for alanine 1135 in the putative "catalytic loop" of the tyrosine kinase domain of the human insulin receptor. A mutation that impairs proteolytic processing into subunits and inhibits receptor tyrosine kinase activity J Biol Chem 268 8060 8069 1:CAS:528:DyaK3sXit1Gqs78%3D 8096518
6. B Charbonnel Schernthaner GP Brunetti, et al. 2005 Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes Diabetologia 48 1093 1104 1:CAS:528:DC%2BD2MXlt1KmtLY%3D 10.1007/s00125-005- 1751-1 15889234 (Pubitemid 40909644)